Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Cortheras investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France.

Marco Metra, M.D., professor of cardiology at the University of Brescia, Italy, and coprincipal investigator of the PreRELAXAHF study, will present the main results from the multicenter, international PreRELAXAHF study at 830 a.m. CET on Sunday, May 31, at the Judges Choice oral abstracts session. Dr. Metra will also present additional analyses of the PreRELAXAHF study during a latebreaking clinical trials session at 1115 a.m. CET on Monday, June 1. Five posters from the PreRELAXAHF study will also be presented from 830 a.m. to 1230 p.m. CET on Monday, June 1.

About Relaxin

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and nonpregnant women, including patients with heart failure.

About Corthera

Corthera Inc. is a private biopharmaceutical company committed to acquiring, developing and commercializing therapies for illnesses in the acute care setting. Cortheras lead product candidate, relaxin, is currently being evaluated in clinical trials for acute heart failure. The company has worldwide rights to develop and commercialize relaxin.